Monthly Archives: January 2015
Synageva BioPharma announces dosing of patients commenced with SBC-103 in Phase 1/2 Study for MPS IIIB and FDA Fast Track Designation Granted
Synageva BioPharma announced that dosing with SBC-103 in patients with MPS IIIB has begun as part of a Phase 1/2 study, and the FDA recently granted SBC-103 Fast Track designation. …
MPS II Non-Treatment Research Studies
Are you or your child at least 3 years old and diagnosed with Mucopolysaccharidosis Type II (MPS II), otherwise known as Hunter syndrome? Do you speak English or Spanish and …
February 28th is Rare Disease Day 2015
Rare Disease Day puts the focus on the daily lives of patients, families and caregivers who are living with a rare disease. Show your support!